Release 5 R6 Ballot (1st Draft)

This page is part of the FHIR Specification (v5.0.0: R5 - STU v6.0.0-ballot1: Release 6 Ballot (1st Draft) (see Ballot Notes ). This is the The current published version in it's permanent home (it will always be available at this URL). is 5.0.0 . For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4

4.4.1.503 4.4.1.509 ValueSet http://hl7.org/fhir/ValueSet/research-study-phase

Biomedical Research and Regulation icon Work Group   Maturity Level : 1 Draft Use Context : Country: World, Not Intended for Production use
Official URL : http://hl7.org/fhir/ValueSet/research-study-phase Version : 5.0.0 6.0.0-ballot1
draft as of 2020-12-28 Computable Name : ResearchStudyPhase
Flags : Experimental, Immutable OID : 2.16.840.1.113883.4.642.3.821

This value set is used in the following places:

4.4.1.503.1 4.4.1.509.1 Definition

Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.

4.4.1.503.2 4.4.1.509.2 Content Logical Definition

 

4.4.1.503.3 4.4.1.509.3 Expansion

This expansion generated 26 Mar 18 Dec 2023

This value set contains 8 concepts

Expansion based on codesystem ResearchStudy Phase Code System v5.0.0 v6.0.0-ballot1 (CodeSystem)

This value set contains 8 concepts

Code System Display Definition
   n-a http://hl7.org/fhir/research-study-phase N/A

Trials without phases (for example, studies of devices or behavioral interventions).

   early-phase-1 http://hl7.org/fhir/research-study-phase Early Phase 1

Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.

   phase-1 http://hl7.org/fhir/research-study-phase Phase 1

Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

   phase-1-phase-2 http://hl7.org/fhir/research-study-phase Phase 1/Phase 2

Trials that are a combination of phases 1 and 2.

   phase-2 http://hl7.org/fhir/research-study-phase Phase 2

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

   phase-2-phase-3 http://hl7.org/fhir/research-study-phase Phase 2/Phase 3

Trials that are a combination of phases 2 and 3.

   phase-3 http://hl7.org/fhir/research-study-phase Phase 3

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

   phase-4 http://hl7.org/fhir/research-study-phase Phase 4

Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.

 

See the full registry of value sets defined as part of FHIR.

Explanation of the columns that may appear on this page:

Lvl A few code lists that FHIR defines are hierarchical - each code is assigned a level. For value sets, levels are mostly used to organize codes for user convenience, but may follow code system hierarchy - see Code System for further information
Source The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance). If the code is in italics, this indicates that the code is not selectable ('Abstract')
Display The display (used in the display element of a Coding ). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code